Patient-Centric & Prospective Medicine Project

The Center for Medicine in the Public Interest (CMPI) has initiated a research program to study the treatment preferences of patients with Idiopathic pulmonary fibrosis (IPF). The project is supported by Intermune, a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. Dr. John F P Bridges PhD, an Associate Professor at the Johns Hopkins Bloomberg School of Public Health and Senior Fellow at CMPI, will serve as the principal investigator of this project. The project will apply the principles of community-based participatory medicine to engage patients, family members, providers and other stakeholder in the design and pilot of a survey instrument to measure the stated-preferences of patients of with IPF for the potential benefits and risk of therapy. A geographically diverse sample of patients with IPF will be then recruited through clinics and advocacy groups to complete the survey. Analysis will use state-of-the-art methods to estimate preferences and results will be disseminated widely.
Sign Up for Our Email Newsletter

RECENT NEWS

Streamline drug approval process

Streamline drug approval process

When Americans don't fill their prescriptions, their illnesses worsen, which drives up healthcare spending....  Read more

‘Transparency’ alone can’t convey the context or complexity of pricing drugs

‘Transparency’ alone can’t convey the context or complexity of pricing drugs

A key problem with Mr. Azar’s transparency effort is that it doesn’t provide consumers with any context or insights into ...  Read more

Safe Harbor Sunshine And Flat Fees: Vital Steps Towards Smarter Drug Spending

Safe Harbor Sunshine And Flat Fees: Vital Steps Towards Smarter Drug Spending

The current system encourages payers to favor medicines that carry higher rebates than lower list-priced drugs....  Read more

DRUGWONKS BLOG